Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Author: AounMickael, CornelyOliver A, GeddesMichelle, GriggAndrew, HaiderShariq, HammondSarah P, HeinzWerner J, HeplerDeborah A, KartsonisNicholas A, MaertensJohan, MeyerRalf G, MullaneKathleen M, OstermannHelmut, RaadIssam, RobertsonMichael N, SchanzUrs, UllmannAndrew J, Van IerselM L P S, WaskinHetty, ZimmerliStefan

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study was conducted to evaluate the safety and effectiveness of posaconazole, an antifungal drug, given intravenously to patients with weakened immune systems. The study showed that posaconazole is safe and effective in preventing fungal infections.
Paper Details　
Original Abstract of the Article :
A two-part (Phase 1B/3), sequential, open-label, multicentre study evaluated the pharmacokinetics (PK) and safety of intravenous (iv) posaconazole given as antifungal prophylaxis to neutropenic patients with AML or myelodysplastic syndrome (MDS) or to recipients at risk of invasive fungal disease (I...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/dkx263

データ提供：米国国立医学図書館（NLM）

Intravenous Posaconazole: A New Oasis in the Desert of Fungal Infections

Invasive fungal infections can be a serious threat, particularly for immunocompromised patients. This study investigates the safety and pharmacokinetics of intravenous posaconazole, an antifungal medication, in patients at risk of invasive fungal disease. The researchers conducted a two-part study, evaluating the drug's effectiveness and safety in patients with various conditions, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and recipients of allogeneic hematopoietic stem cell transplantation (HSCT).

A Safe and Effective Antifungal Weapon

The study found that intravenous posaconazole was well tolerated and effective in preventing invasive fungal infections in patients at risk. This provides a valuable tool for clinicians who are seeking to protect their patients from the potentially deadly consequences of these infections. The study also provides important information about the drug's pharmacokinetic profile, which can help to guide optimal dosing and administration.

A Beacon of Hope in the Fungal Infection Desert

This research offers a glimmer of hope for patients who are at risk of invasive fungal infections. It provides evidence-based support for the use of intravenous posaconazole as a safe and effective prophylactic treatment. This research is like finding a hidden oasis in the desert of fungal infections, offering a fresh source of hope and protection for those who are most vulnerable.

Dr. Camel's Conclusion

This study underscores the importance of ongoing research to develop new and effective treatments for challenging infections. Intravenous posaconazole emerges as a promising tool for preventing invasive fungal infections in vulnerable patients. This research is a testament to the dedication of scientists and clinicians who are constantly working to improve the health and well-being of those who are most in need.

Date :
  1. Date Completed 2018-07-02
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

28961714

DOI: Digital Object Identifier

10.1093/jac/dkx263

Related Literature

Article Analysis
・Side Effects of posaconazole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.